financetom
Business
financetom
/
Business
/
Renasant beats Q2 adjusted EPS expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Renasant beats Q2 adjusted EPS expectations
Jul 22, 2025 1:59 PM

Overview

* Renasant ( RNST ) Q2 adjusted EPS beats analyst expectations, per LSEG data

* Net income impacted by merger expenses and acquisition provisions

* Net interest income rises due to merger with The First Bancshares

Outlook

* Company did not provide specific future guidance or projections

Result Drivers

* MERGER IMPACT - Merger with The First Bancshares increased net interest income and noninterest income

* CREDIT PROVISION - Day 1 acquisition provision for credit losses impacted net income

* EXPENSE INCREASE - Noninterest expenses rose due to merger-related costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $0.69 $0.63 (6

Adjusted Analysts

EPS )

Q2 EPS $0.01

Q2 Net $1.02

Income mln

Q2 Net $218.86

Interest mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy"

* Wall Street's median 12-month price target for Renasant Corp ( RNST ) is $41.00, about 6.2% above its July 21 closing price of $38.46

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Intra-Cellular Therapies, Sandoz Settle CAPLYTA Patent Litigation
Update: Intra-Cellular Therapies, Sandoz Settle CAPLYTA Patent Litigation
Jan 10, 2025
12:37 PM EST, 01/10/2025 (MT Newswires) -- (Updates with recent stock movement in the final paragraph.) Intra-Cellular Therapies ( ITCI ) said Friday it reached a settlement with Sandoz to resolve patent litigation over its central nervous system disorder drug CAPLYTA. The settlement allows Sandoz to sell generic versions of CAPLYTA starting July 1, 2040, or earlier under specific conditions,...
Update: Constellation Energy Shares Surge After Agreeing to Acquire Calpine for $16.4 Billion
Update: Constellation Energy Shares Surge After Agreeing to Acquire Calpine for $16.4 Billion
Jan 10, 2025
12:37 PM EST, 01/10/2025 (MT Newswires) -- (Reflects latest stock move in the headline and first two paragraphs.) Constellation Energy's ( CEG ) shares surged after it said it has agreed to acquire Calpine in a cash and stock transaction valued at about $16.4 billion, the energy companies said Friday. The stock was up nearly 24% in recent intraday trading....
Delta Air Lines Jet Evacuated After Aborted Takeoff in Atlanta Due to Engine Issue
Delta Air Lines Jet Evacuated After Aborted Takeoff in Atlanta Due to Engine Issue
Jan 10, 2025
12:33 PM EST, 01/10/2025 (MT Newswires) -- Delta Air Lines ( DAL ) Flight 2668's crew aborted takeoff at the Atlanta airport Friday morning due to a reported engine issue, according to the Federal Aviation Administration. Passengers exited the jet on the runway of the Hartsfield-Jackson Atlanta International Airport, the FAA said. The aborted takeoff left four people injured, according...
Westlake Earnings Approach Low Point, Offering 'Attractive' Investment Opportunity, UBS Says
Westlake Earnings Approach Low Point, Offering 'Attractive' Investment Opportunity, UBS Says
Jan 10, 2025
12:36 PM EST, 01/10/2025 (MT Newswires) -- Westlake's (WLK) earnings and valuation are nearing a low point, creating an attractive investment opportunity before potential positive changes in macroeconomic data later this year, UBS Securities said in a note emailed Friday. Global utilization rates for polyvinyl chloride and caustic, Westlake's main products, reached bottom in 2024 and are expected to gradually...
Copyright 2023-2026 - www.financetom.com All Rights Reserved